🔗 Share this article

While the United States proceeds with historic adjustments to its vaccine schedules, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations during the pandemic and has concentrated on alleged fatalities after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Program

Agency leaders planned to reveal radical changes to the childhood immunization program recently, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with much of the international standard with no evidence for benefit. This reveal has been pushed back until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to speak at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this year.

A Shift at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain childhood immunization guidelines in the US in order to be more like Denmark, a country with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Expertise

The appointee has no apparent track record in pharmaceutical research, approval processes or leadership, which has been customary for previous leaders of the CBER. She has served at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in managing a sizeable institution. She has no expertise in industry regulation.”

Former commissioners of the center would “grasp legal statutes and the research of drug development”, said Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who led CBER have had.”

CDER has an vast workload at the FDA, she pointed out.

“The public just pays attention on the new drug program, but the generic drug division clears thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be managed,” Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a substantial administrative component to the job, which oversees over 5,000 employees. “It’s a enormous administrative position, if you execute it properly,” she added.

Agency Reaction and Controversial Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among regulatory chiefs on vaccines, a representative stated that the “inquiries rely on incorrect premises”.

“This background aligns with the duties of her position,” the official explained, citing the time Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a contentious expedited drug-approval program that allegedly troubled her predecessors. “By what process are these drugs being selected for this fast-track system? Who takes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards laxer rules of pharmaceuticals, except for vaccines.”

Established Track Record on Immunizations

Concerning vaccines, Høeg has a more established, if troubling, track record, critics have noted. She published a research paper using non-validated volunteer-provided data to determine the incidence of heart inflammation following COVID-19 immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the current administration encompassed changing regulations for novel immunizations and halting “non-essential” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has allegedly suggested barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who begins with her preconceived notions and reverse-engineers to retrofit the data in a extremely misleading, dishonest fashion,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|